Oncology’s PA Puzzle: Who Appeals, Who Doesn’t, and Why It Matters

Prior authorization (PA) denials are a constant challenge in oncology—but not all providers respond the same way. Some appeal, while others let denials go unchallenged.?

Our latest analysis on PA denials revealed surprising insights, including:?

• Less sophisticated community oncology practices appeal PA denials the most (56%)?

• Highly sophisticated practices appeal far less (28%)—despite having more resources?

• Even in integrated delivery networks, the least integrated systems are the most likely to appeal?

What should manufacturers do to streamline PA approvals and support providers where they need it most??

We break it all down in our latest blog post.